Page last updated: 2024-11-11

10-hydroxyamitriptyline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

10-hydroxyamitriptyline: metabolite of amitryptyline; RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6454906
CHEMBL ID3544582
CHEBI ID174098
MeSH IDM0104512

Synonyms (24)

Synonym
CHEBI:174098
(2e)-2-[3-(dimethylamino)propylidene]tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaen-9-ol
64520-05-4
e-10-hydroxyamitriptyline
SMP2_000003
10-hydroxyamitriptyline
1159-82-6
5h-dibenzo(a,d)cyclohepten-10-ol, 5-(3-(dimethylamino)propylidene)-10,11-dihydro-, (e)-
unii-8646k54i21
10-hydroxyamitriptyline, (e)-
8646k54i21 ,
trans-10-hydroxyamitriptyline
(e)-10-hydroxyamitriptyline
10-hydroxyamitriptyline, (e)-(+/-)-
5h-dibenzo(a,d)cyclohepten-10-ol, 5-(3-(dimethylamino)propylidene)-10,11-dihydro-, (5e)-
CHEMBL3544582
(2e)-2-[3-(dimethylamino)propylidene]tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-9-ol
5-(3-(dimethylamino)propylidene)-10,11-dihydro-5h-dibenzo[a,d]cyclohepten-10-ol
DTXSID50873786
Q27269700
(+/-)-e-5-[3-(dimethylamino)propylidene]-10.11-dihydro-5h-dibenzo[a,d]cyclohepten-10-ol
amitriptyline metabolite (+/-)-
5h-dibenzo[a,d]cyclohepten-10-ol, 5-[3-(dimethylamino)propylidene]-10,11-dihydro-, (5e)-
(e)-5-(3-(dimethylamino)propylidene)-10,11-dihydro-5h-dibenzo[a,d][7]annulen-10-ol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic tricyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (30.77)18.7374
1990's8 (61.54)18.2507
2000's1 (7.69)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.14%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]